There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC – Research Report) and Erasca (ERAS – Research Report) with bullish sentiments.
Celcuity (CELC)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Celcuity today and set a price target of $27.00. The company’s shares closed last Wednesday at $18.16, close to its 52-week high of $18.95.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of
Currently, the analyst consensus on Celcuity is a Strong Buy with an average price target of $30.33, a 71.4% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $24.00 price target.
See today’s best-performing stocks on TipRanks >>
Erasca (ERAS)
H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Erasca today and set a price target of $8.00. The company’s shares closed last Wednesday at $2.06.
According to TipRanks.com, Maldonado is a 5-star analyst with an average return of
Currently, the analyst consensus on Erasca is a Strong Buy with an average price target of $7.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CELC:
- Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
- CELC Upcoming Earnings Report: What to Expect?
- Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
- Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
